Related Experiment Video
Updated: Jun 5, 2025

Modeling Neuronal Death and Degeneration in Mouse Primary Cerebellar Granule Neurons
Published on: November 6, 2017
Engineered Cyclotide Blocks Neuronal Excitotoxicity
Daryl Ariawan1, Julia van der Hoven1, Nicolle Morey1
1Dementia Research Centre, Macquarie Medical School, Macquarie University 2109 Sydney, Australia.
Abstract:
Cyclotides are naturally occurring cyclic peptides with three disulfide bonds, offering remarkable stability. In neurological disorders, the formation of a complex between postsynaptic density protein 95 and NMDA receptors (NMDARs) can lead to neuronal cell death. In this study, we modified the MCoTI-II cyclotide backbone with polyarginines for enhanced intracellular delivery and grafted a 9-amino acid PSD-95-NMDAR inhibitor sequence, NR2B9c, into loop 6. We found that incorporating polyarginines into the cyclotide backbone significantly improved uptake into neuronal cells. Primary neurons treated with the NR2B9c cyclotide (c5R-NR2B9c) prevented cell death in response to high concentrations of N-methyl-d-aspartate (NMDA), demonstrating protection from excitotoxicity. Administration of c5R-NR2B9c in a chemically induced seizure model in mice resulted in increased survival and reduced seizure severity. Overall, we show that modifying cyclotides with a polyarginine backbone can enhance the delivery of therapeutic peptides into neuronal cells, which can be utilized to administer therapeutic peptides for the protection of neuronal cells from excitotoxicity.
Related Concept Videos
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Drugs Affecting Neurotransmitter Synthesis
Antiepileptic Drugs: Glutamate Antagonists
Neurochemical Transmission: Sites of Drug Action
Depolarizing Blockers: Pharmocokinetics

